Right treatment, right time and right place – public consultation about proposals for a new vision of urgent care
You will be aware by now that we are currently running a public consultation into proposals to create a new urgent care hub ‘one stop shop’ for the borough.
We have previously sent you information for display in your practice, however we have had concerns from stakeholders that this information is not visible.
We have arranged for this information to be redistributed this week. Can I ask you to look out for this information arriving and display it in a prominent position where patients can see it.
If you would like additional supplies please contact:
0191 217 2670 or email: STCCG@sotw.nhs.uk and mark for the attention of the communications team.
Your help in doing this is very much appreciated.
Dr David Hambleton
Chief Officer -South Tynesdie CCG
- News Stream
- Winter Access Services
- Tackle High BP
- 2019-20 South Tyneside Council Flu Service
- 2019-20 Gateshead Council Flu Service
- GP2P Service
- NHS Health Checks - Gateshead
- NHS Health Checks - South Tyneside
- Think Pharmacy First Gateshead
- Think Pharmacy First ST
- EHC-South Tyneside
- Contact Us
Right treatment, right time and right place – public consultation about proposals for a new vision of urgent care in South Tyneside
This is a reminder that all contractors must submit their annual contract monitoring documentation and complete their Information Governance assurances.
The deadline for both of these for 2013/14 is
31 March 2014.
Further detail about both can be found below.
Every Pharmacy needs to submit the following Documentation to the area team.
Assistant Primary Care Commissioning Support
County Durham, Darlington & Tees Area Team
Cumbria, Northumberland, Tyne & Wear Area Team
Sunderland Enterprise Park
Direct Dial: 0191 502 6572
Switch Board: 0191 502 6542
Fax: 01325 553096
All NHS Providers, including community pharmacies, need to provide information governance assurances to the NHS on an annual basis. This is done via the completion of the online information governance toolkit (Version 11).
Further information on the information governance requirements for this year can be found on the PSNC Website. This can be accessed by clicking HERE.
The MHRA has issued class 2 drug alerts for Wockhardt and Pinewood Laboratories following manufacturing site inspections.
Pharmacies will need to take action within the next 48 hours and should note the large number of products affected this time.
16 different prescription only medicines in a variety of strengths made by Wockhardt Ltd are affected following manufacturing deficiencies identified by the MHRA at Wockhardt’s Waluj site in India.
The medicines affected by the precautionary recall include those used for the treatment of infections, high blood pressure, diabetes, epilepsy, depression, schizophrenia, Parkinson’s disease, dementia in Alzheimer’s patients and thyroid conditions.
Full Details of the recalls
1. Class 2 Drug Alert (Action within 48 Hours): Multiple products - Wockhardt UK Limited (EL (13)A/19) - This includes a list of all the medicines that are affected by the precautionary recall.
2. Class 2 Medicines recall (Action within 48 Hours): Erythromycin Oral Suspension - Pinewood Laboratories Limited (EL (13)A/20)
Patients do not need to return their medicines because there is no evidence that the medicines affected by the precautionary recall in the UK are defective. Therefore, it’s important that people continue to take their medicines as prescribed.
This is not a patient level recall because although the medicines that are affected have not been manufactured to Good Manufacturing Practice (GMP) standards, there is no evidence of a patient safety risk from medicines that have been sold in the UK. However, the MHRA has to act in the interests of public health as poor manufacturing standards cannot be allowed to continue.
The deficiencies identified by the MHRA during a routine inspection in March included a low risk of cross-contamination because of poor cleaning practices and defects in building fabric and the ventilation systems at the site. There was also evidence of forged documents relating to staff training records that had been rewritten. The MHRA is working with Wockhardt and other international regulators to resolve these issues.
Gerald Heddell, the MHRA’s Director of Inspection, Enforcement and Standards, said:
“This is a precautionary recall. People can be reassured that there is no evidence that medicines made by Wockhardt are defective so it’s important people continue to take their medicines as prescribed.
“All batches of medicines manufactured outside the European Union are tested on importation to the UK before they reach patients. However, we have taken this precautionary action because the medicines have not been manufactured to the right regulatory standards.
“We are working with the Department of Health to ensure that people have access to the medicines they need. Anyone who has questions should speak to their pharmacist or GP.”
The medicines that are involved in the recall are available for patients from alternative manufacturers in most cases, either in equivalent strengths or varying strengths. Where there are no alternative manufacturers of the same medicines, substitutes are available and these should be selected by a healthcare professional.
The Department of Health is working closely with the companies concerned to help ensure that patients are able to get their medicines when they need them.
Copies of our older Paper Based News Letters (The LPC News) can be found by clicking below.